Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

NCT04205968 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT04205968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2020
Completion date
August 1, 2027
Enrollment
94 (estimated)
Sites
536

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic small intestinal adenocarcinoma, stage iii small intestinal adenocarcinoma ajcc v8, stage iiia small intestinal adenocarcinoma ajcc v8, stage iiib small intestinal adenocarcinoma ajcc v8, stage iv small intestinal adenocarcinoma ajcc v8